The Tumor Necrosis Factor Superfamily of Cytokines in the Inflammatory Myopathies: Potential Targets for Therapy

Table 1

Tumor necrosis factor inhibitors for treating inflammatory myopathies: published trial results for infliximab and etanercept.

Compound and treatment regimen	Diagnosis/patients continued to end point	Follow-up time	Clinical outcome at end point	Reference
infliximab 6 mg/kg 4-weekly or more frequent	R-JDM/5	32 to 130 weeks	I (5/5)	[19]
infliximab 10 mg/kg (week 0, 2, 6, 14)	R-DM/1; R-PM/4; R-IBM/4	16 weeks	NC (1/1); I (2/4) W (2/4); I (1/4) NC (3/4)	[20]
infliximab 10 mg/kg (week 0, 2, 4)	R-DM/1; R-PM/1	12 weeks	I (1/1); I (1/1)	[21]
infliximab 10 mg/kg (week 20); infliximab 10 mg/kg (week 14, 18, 22)	R-DM/1; R-PM/1	66 weeks	I (1/1); I (1/1)	[22]
infliximab 10 mg/kg (week 0, 2, 6, 14, 22)	PM/2	26 weeks	I (2/2)	[23]
infliximab 8 mg/kg (week 0, 2, 6)	R-DM/1	6 weeks	I (1/1)
infliximab 10 mg/kg (week 0, 2, 4, 6, 9)	R-PM/1	69 weeks	I (1/1)	[24]
infliximab 3 mg/kg (week 0, 2, 6, every 8) and etanercept 25 mg twice weekly	R-DM/1; R-PM/2	36 to 96 weeks	PR (1/1); I (2/2)	[25]
etanercept 25 mg twice weekly	R-DM/1	56 weeks	I (1/1)	[26]

Abbreviations: dermatomyositis (DM), improved (I), inclusion body myositis (IBM), juvenile DM (JDM), no change (NC), partial response (PR), polymyositis (PM), refractory DM/PM/IBM (R-DM/PM/IBM), worsened (W).